by Anis Fahandej-Sadi | Jun 5, 2025
Cancer treatment has advanced dramatically, but a central challenge remains: the newest tools in our arsenal are shockingly expensive. CAR T-cell therapies exemplify this—they’re amazing at fighting blood cancers, but a single treatment costs upwards of...
by Kevin Robb | May 22, 2025
For the first time, mesenchymal stromal cells (MSCs) can be used in routine clinical practice under the nod of regulatory approval in the United States. The MSC product known as Ryoncil was made available to patients in March 2025 following a historic decision from...
by Laine Bodnar | Mar 18, 2025
For life science graduates exploring career options, the regulatory affairs function is where scientific expertise meets real-world impact. Regulatory affairs professionals play a crucial role in bringing regenerative medicine – including cell and gene therapies –...
by Cal Strode | Mar 11, 2025
“Every administration has its headwinds and tailwinds” said Tim Hunt, CEO, Alliance for Regenerative Medicine (ARM), when examining the impact of the two most recent U.S. administrations at ARM’s 2025 State of the Industry Briefing in January. Credit: Alliance for...
by Cal Strode | Jan 20, 2025
2025 marks the third time I’ve covered the Alliance for Regenerative Medicine (ARM) State of the Industry Briefing for Signals. In 2024’s installation, I noted the strong emphasis on the cell and gene therapy (CGT) industry’s acceleration, driven by scientific...
by Anis Fahandej-Sadi | Dec 5, 2024
If you’re reading this, you’re probably aware of the massive strides the cell and gene therapy (CGT) industry has made in the last few years. Between 2017 and 2022, six CGT products were approved by the U.S. Food and Drug Administration, but we saw eight approvals in...
Comments